These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24101713)

  • 21. Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations.
    Santos KF; Oliveira TT; Nagem TJ; Pinto AS; Oliveira MG
    Pharmacol Res; 1999 Dec; 40(6):493-6. PubMed ID: 10660947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New evidence for nicotinic acid treatment to reduce atherosclerosis.
    Montecucco F; Quercioli A; Dallegri F; Viviani GL; Mach F
    Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1457-67. PubMed ID: 20936932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
    Olsson AG
    Expert Opin Pharmacother; 2010 Jul; 11(10):1715-26. PubMed ID: 20518616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The growing importance of PON1 in cardiovascular health: a review.
    Macharia M; Hassan MS; Blackhurst D; Erasmus RT; Matsha TE
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):443-53. PubMed ID: 22673025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance.
    Linke A; Sonnabend M; Fasshauer M; Höllriegel R; Schuler G; Niebauer J; Stumvoll M; Blüher M
    Atherosclerosis; 2009 Jul; 205(1):207-13. PubMed ID: 19131065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Advances of study on glucose and lipids metabolism of chlorogenic acid regulating].
    Huang Z; Chang C
    Wei Sheng Yan Jiu; 2008 Sep; 37(5):637-9. PubMed ID: 19069672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome.
    Aye MM; Kilpatrick ES; Afolabi P; Wootton SA; Rigby AS; Coady AM; Sandeman DD; Atkin SL
    Diabetes Obes Metab; 2014 Jun; 16(6):545-52. PubMed ID: 24401089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid-lowering drugs and circulating adiponectin.
    Wanders D; Plaisance EP; Judd RL
    Vitam Horm; 2012; 90():341-74. PubMed ID: 23017722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipidology.
    Nicholls SJ
    Cardiol Clin; 2018 May; 36(2):xiii. PubMed ID: 29609763
    [No Abstract]   [Full Text] [Related]  

  • 32. Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?
    Handelsman Y; Fonseca V; Rosenstock J
    Expert Rev Clin Pharmacol; 2012 Jan; 5(1):43-54. PubMed ID: 22142158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of puerarin on blood pressure, blood lipid and renal structure of cold-induced hypertensive mice].
    Pan ZJ; Yan GL; Wang LP; Xu XX; Pan L
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2011 Nov; 27(4):436-8. PubMed ID: 22295519
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
    Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance.
    Rabar S; Harker M; O'Flynn N; Wierzbicki AS;
    BMJ; 2014 Jul; 349():g4356. PubMed ID: 25035388
    [No Abstract]   [Full Text] [Related]  

  • 36. Nicotinic Acid and new-onset diabetes.
    Katsiki N; Athyros VG; Karagiannis A; Mikhailidis DP
    Horm Metab Res; 2015 Jun; 47(7):544-5. PubMed ID: 25137408
    [No Abstract]   [Full Text] [Related]  

  • 37. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
    Brown BG; Zhao XQ
    Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
    Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF
    Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Niacin stimulates adiponectin secretion through the GPR109A receptor.
    Plaisance EP; Lukasova M; Offermanns S; Zhang Y; Cao G; Judd RL
    Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E549-58. PubMed ID: 19141678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nicotinic acid promotes sleep through prostaglandin synthesis in mice.
    Szentirmai É; Kapás L
    Sci Rep; 2019 Nov; 9(1):17084. PubMed ID: 31745228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.